10results about "Antibodies" patented technology

The present application provides methods, compositions and kits for determining SHD-catalyzed antibody levels in a biological sample and for treating or preventing protein aggregation disease (PAD) in an individual. Catalytic antibodies that specifically recognize amyloid beta (A beta) peptides and methods of using the same are also provided.

A method for producing an antibody κ-type light chain having enzyme activity or improved enzyme activity includes: a modification step for modifying a polynucleotide encoding an antibody κ-type light chain in which the variable region is a polypeptide comprising an amino acid sequence in which the 95th amino acid residue from the N-terminal of the variable region by the Kabat classification is a proline residue so that the proline residue is deleted or substituted to obtain a polynucleotide encoding an antibody κ-type light chain in which the variable region is a polypeptide comprising an amino acid sequence in which the 95th amino acid residue from the N-terminal of the variable region by the Kabat classification is deleted or an amino acid residue other than a proline residue; and an expression step for expressing the antibody κ-type light chain having enzyme activity by an intracellular or extracellular expression system using an expression vector including the polynucleotide encoding an antibody κ-type light chain from after the modification step.

To provide methods for stably producing an antibody enzyme excellent in storage stability.SOLUTION: There is disclosed a method for producing a κ light chain antibody comprising the steps of: expressing a κ light chain antibody in an intracellular or extracellular expression system by using an expression vector comprising a polynucleotide that encodes the κ light chain antibody; subjecting the expressed product to column chromatography using a column containing a first filler to obtain a crude product containing the κ light chain antibody; adding metal ions to the crude product containing the κ light chain antibody so as to obtain a crudely purified product containing a complex of κ light chain antibody with the metal ions; purifying the crudely purified product containing the κ light chain antibody-metal complex by column chromatography using a column containing a second filler from the crudely purified product containing the complex of the κ light chain antibody, to obtain a purified κ light chain antibody-metal complex; and removing the metal ions from the purified κ light chain antibody-metal complex so as to obtain a purified product of the κ light chain antibody.SELECTED DRAWING: None

The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (Aβ) peptides and methods of use thereof.

The present invention discloses a method for preparing L-glufosinate ammonium by biological enzymatic de-racemization, a glufosinate ammonium dehydrogenase mutant and a use thereof. The method for preparing L-glufosinate ammonium by biological enzymatic de-racemization includes catalyzing D,L-glufosinate ammonium as a raw material by a multi-enzyme catalysis system to obtain L-glufosinate ammonium. The enzyme catalysis system includes D-amino acid oxidase for catalyzing D-glufosinate ammonium in the D,L-glufosinate ammonium to 2-carbonyl-4-[hydroxy(methyl)phosphonyl]butanoic acid, and a glufosinate ammonium dehydrogenase mutant for catalytically reducing 2-carbonyl-4-[hydroxy(methyl)phosphonyl]butanoic acid to L-glufosinate ammonium. The glufosinate ammonium dehydrogenase mutant is obtained by mutation of glufosinate-ammonium dehydrogenase in wild fungi Thiopseudomonas denitrificans at a mutation site of V377S. The glufosinate ammonium dehydrogenase mutant in the present invention has better catalytic efficiency. When racemic D, L-glufosinate ammonium is used as a substrate for a catalytic reaction, the conversion rate is much higher than the conversion rate of a wild-type enzyme, and the yield of 2-carbonyl-4-[hydroxy(methyl)phosphonyl]butanoic acid (PPO for short) is also greatly improved.

This application provides methods, compositions, and kits for determining the level of SHD catalytic antibodies in biological samples and for treating or preventing protein aggregation disorders (PAD) in individuals. It also provides catalytic antibodies that specifically recognize amyloid β (Aβ) peptide and methods for using them.

The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (Aβ) peptides and methods of use thereof.

The present invention provides modified catalytic antibody 38C2 with arylation of the reactive lysine residue (Lys99). The Lys99 residue is arylated with a heteroaryl methyl sulfonyl compound such as methylsulfone phenyl oxadiazole (MS-PODA). The invention also provides antibody conjugated agents (e.g., antibody drug conjugates) that contain an agent moiety that is site-specifically conjugated to 38C2 via a methyl sulfonyl compound. Further provided in the invention are methods of making the antibody conjugated agents and therapeutic applications of the antibody conjugated agents.

The present invention provides antibody compounds that contain a substitution of arginine for the reactive lysine residue (Lys99) in the hydrophobic cleft (38C2_Arg). The invention also provides antibody drug conjugate compounds (ADCs) that contain cargo moieties that are site-specifically conjugated to the engineered arginine residue in the 38C2_Arg variant antibody. Further provided in the invention are therapeutic applications of the compounds.

The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (Aβ) peptides and methods of use thereof.